InvestSMART

BCAL Diagnostics Limited (ASX:BDX)

ALERT: Price-sensitive ASX Announcement for BDX
Current share price for BDX : $0.072 -0.053 (-42.40%)+
Announcement
Release
21 Jan 2026 8:53AM
Price at Release
$0.125
Full Release
download
Summary
BCAL Diagnostics Limited, an Australian healthcare company focused on early cancer detection, released its Quarterly Activities and Appendix 4C Cash Flow Report for the quarter ending 31 December 2025. The company announced the readiness of its Avantect® pancreatic and ovarian cancer tests for launch in Australia, receiving national ethics approval for the BREASTESTplus™ registry. Financially, BCAL reported a cash balance of $3.3 million, with a $10 million convertible note facility approved, and a $2.5 million R&D tax refund received. Key operational highlights include progress in launching new cancer tests and strengthening the clinical foundation of BREASTESTplus™.
Key Points
  • Avantect® pancreatic and ovarian cancer tests ready for Australian launch in January 2026.
  • National ethics approval received for the BREASTESTplus™ registry.
  • Cash balance of $3.3 million reported as of 31 December 2025.
  • Approval for a $10 million convertible note facility with $5 million committed.
  • Received a $2.5 million R&D tax refund from the Australian Taxation Office.
  • Continued sales and clinical engagement for the BREASTESTplus™ blood test.
  • Focus on converting validated science into real-world clinical impact.
  • Strengthened clinical foundation of BREASTESTplus™, with new Australian data supporting its use.
  • Operational updates include securing UK regulatory approvals and international milestones for Avantect® tests.
  • Financial report prepared according to Australian Accounting Standards.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.